<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="myocardium and improve cardiac function: Co-enzyme Q, Vitamin C, sodium" exact="creatine" post="phosphate COVID-19 patient with arrhythmia Electrocardiogram abnormal, clinic symptoms"/>
 <result pre="granulocyte colony-stimulating factor (GCSF), IP10, MCP1, macrophage inflammatory protein 1" exact="alpha" post="(MIP1Î±), and TNF-Î± were significantly elevated in ICU patients,"/>
 <result pre="Coronavirus Disease 2019 (Tentative seventh version) recommends the use of" exact="lopinavir" post="and/or ritonavir, both of which are protease inhibitors and"/>
 <result pre="with statins or for patients with coronary heart disease [41]." exact="Chloroquine" post="can cause cardiac arrhythmias and even cardiac arrest, the"/>
 <result pre="arrest, the most serious adverse reaction [42]. For COVID-19 patients," exact="azithromycin" post="and hydroxychloroquine can increase the risk of different arrhythmias,"/>
 <result pre="most serious adverse reaction [42]. For COVID-19 patients, azithromycin and" exact="hydroxychloroquine" post="can increase the risk of different arrhythmias, such as"/>
 <result pre="failure rate when used in combination with drugs such as" exact="azithromycin" post="and quinolones [44]. Interferons may affect the cardiac conduction"/>
 <result pre="version) recommends the use of antiviral drugs, including Î±-IFN, lopinavir/ritonavir," exact="ribavirin" post="(combined with one of the above medications), chloroquine and"/>
 <result pre="Î±-IFN, lopinavir/ritonavir, ribavirin (combined with one of the above medications)," exact="chloroquine" post="and Arbidol [46]. Beyond that, many medications have been"/>
 <result pre="antiviral therapy combination of interferon beta-1b (IFN Î²-1b), lopinavir/ritonavir, and" exact="ribavirin" post="may help patients with mild to moderate COVID-19 recover"/>
 <result pre="binding site or changing its configuration may be potential approaches." exact="Chloroquine" post="inhibits viral infection by increasing the pH of the"/>
 <result pre="fusion and interfering with glycosylation at the ACE2 terminal [54]." exact="Chloroquine" post="phosphate has been proven to effectively inhibit SARS-CoV-2 in"/>
 <result pre="quickly reduced Ang II levels [58], while the administration of" exact="captopril" post="reduced IFN-Î³, prostaglandin E2 (PGE2), and TGF-Î²1 levels and"/>
 <result pre="II levels [58], while the administration of captopril reduced IFN-Î³," exact="prostaglandin E2" post="(PGE2), and TGF-Î²1 levels and increased interleukin 4 (IL-4)"/>
 <result pre="respiratory syndromeChinese J Cardiol312003727730 41WangpatharawanitP.SungkanuparphS.Switching lopinavir/ritonavir to atazanavir/ritonavir vs adding" exact="atorvastatin" post="in HIV-infected patients receiving second-line antiretroviral therapy with hypercholesterolemia:"/>
 <result pre="Dermatol.11619805875916990871 43ChorinE.DaiM.ShulmanE.WadhwaniL.Bar-CohenR.BarbhaiyaC.The QT interval in patients with COVID-19 treated with" exact="hydroxychloroquine" post="and azithromycinNat. Med.222020808809 44ZJ.The treatment and explanation of novel"/>
 <result pre="Chan, et al, Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
 <result pre="the recognition of the 2019-nCoV by human ACE2bioRxiv5812020221224 54WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30202026927132020029 55GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
</results>
